Cargando…
Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome
Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823505/ https://www.ncbi.nlm.nih.gov/pubmed/27110565 http://dx.doi.org/10.1155/2016/5312674 |
_version_ | 1782425932209848320 |
---|---|
author | Erturk, Biray Karaca, Emin Aykut, Ayca Durmaz, Burak Guler, Ahmet Buke, Baris Yeniel, Ahmet Ozgur Ergenoglu, Ahmet Mete Ozkinay, Ferda Ozeren, Mehmet Kazandi, Mert Akercan, Fuat Sagol, Sermet Gunduz, Cumhur Cogulu, Ozgur |
author_facet | Erturk, Biray Karaca, Emin Aykut, Ayca Durmaz, Burak Guler, Ahmet Buke, Baris Yeniel, Ahmet Ozgur Ergenoglu, Ahmet Mete Ozkinay, Ferda Ozeren, Mehmet Kazandi, Mert Akercan, Fuat Sagol, Sermet Gunduz, Cumhur Cogulu, Ozgur |
author_sort | Erturk, Biray |
collection | PubMed |
description | Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method. A total of 56 patients underwent invasive prenatal testing; 23 cases were carrying Down Syndrome affected fetuses, and 33 control cases carrying unaffected, normal karyotype fetuses were included for comparison. Indications for invasive prenatal testing were advanced maternal age, increased risk of Down Syndrome in screening tests, and abnormal finding in the sonographic examination. In both the study and control groups, all the pregnant women were at 17th and 18th week of gestation. miRNA expression levels were measured using real-time RT-PCR. Results. Significantly increased maternal plasma levels of miR-3156 and miR-99a were found in the women carrying a fetus with Down Syndrome. Conclusion. Our results provide a basis for multicenter studies with larger sample groups and microRNA profiles, particularly with the microRNAs which were found to be variably expressed in our study. Through this clinical research, the utility of microRNAs in noninvasive prenatal testing can be better explored in future studies. |
format | Online Article Text |
id | pubmed-4823505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48235052016-04-24 Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome Erturk, Biray Karaca, Emin Aykut, Ayca Durmaz, Burak Guler, Ahmet Buke, Baris Yeniel, Ahmet Ozgur Ergenoglu, Ahmet Mete Ozkinay, Ferda Ozeren, Mehmet Kazandi, Mert Akercan, Fuat Sagol, Sermet Gunduz, Cumhur Cogulu, Ozgur Biomed Res Int Research Article Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method. A total of 56 patients underwent invasive prenatal testing; 23 cases were carrying Down Syndrome affected fetuses, and 33 control cases carrying unaffected, normal karyotype fetuses were included for comparison. Indications for invasive prenatal testing were advanced maternal age, increased risk of Down Syndrome in screening tests, and abnormal finding in the sonographic examination. In both the study and control groups, all the pregnant women were at 17th and 18th week of gestation. miRNA expression levels were measured using real-time RT-PCR. Results. Significantly increased maternal plasma levels of miR-3156 and miR-99a were found in the women carrying a fetus with Down Syndrome. Conclusion. Our results provide a basis for multicenter studies with larger sample groups and microRNA profiles, particularly with the microRNAs which were found to be variably expressed in our study. Through this clinical research, the utility of microRNAs in noninvasive prenatal testing can be better explored in future studies. Hindawi Publishing Corporation 2016 2016-03-24 /pmc/articles/PMC4823505/ /pubmed/27110565 http://dx.doi.org/10.1155/2016/5312674 Text en Copyright © 2016 Biray Erturk et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Erturk, Biray Karaca, Emin Aykut, Ayca Durmaz, Burak Guler, Ahmet Buke, Baris Yeniel, Ahmet Ozgur Ergenoglu, Ahmet Mete Ozkinay, Ferda Ozeren, Mehmet Kazandi, Mert Akercan, Fuat Sagol, Sermet Gunduz, Cumhur Cogulu, Ozgur Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome |
title | Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome |
title_full | Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome |
title_fullStr | Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome |
title_full_unstemmed | Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome |
title_short | Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome |
title_sort | prenatal evaluation of microrna expressions in pregnancies with down syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823505/ https://www.ncbi.nlm.nih.gov/pubmed/27110565 http://dx.doi.org/10.1155/2016/5312674 |
work_keys_str_mv | AT erturkbiray prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT karacaemin prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT aykutayca prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT durmazburak prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT gulerahmet prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT bukebaris prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT yenielahmetozgur prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT ergenogluahmetmete prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT ozkinayferda prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT ozerenmehmet prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT kazandimert prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT akercanfuat prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT sagolsermet prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT gunduzcumhur prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome AT coguluozgur prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome |